|
The Board of Marksans Pharma at its meeting held on 15 June 2021 approved the following issue of convertible warrants on preferential basis:
(a) 10,00,000 convertible warrants to Mark Saldanha (Promoter of the Company) at a price of Rs 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018; and
(b) 4,93,24,324 convertible warrants to OrbiMed Asia IV Mauritius FVCI at a price of Rs 74.00 per warrant, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.
|